Overview

Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of Toripalimab combined with Chidamide in the treatment of relapsed/refractory peripheral T-cell lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
toripalimab